In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 2, 2015, Pages 321-327

  Joseph, Kusumam ^a   Tholanikunnel, Tracy E ^b   Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

ACE inhibitor; aliskiren; Angioedema; bradykinin; enalapril

Indexed keywords

ALISKIREN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; RENIN INHIBITOR; 2-MERCAPTOMETHYL-3-GUANIDINOETHYLTHIOPROPIONIC ACID; 3 MERCAPTOPROPIONIC ACID; AMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; FUMARIC ACID DERIVATIVE; RENIN;

ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MONOTHERAPY; PLASMA; PROTEIN DEGRADATION; PROTEIN METABOLISM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PULMONARY ARTERY;

3-MERCAPTOPROPIONIC ACID; AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; ENDOTHELIAL CELLS; FUMARATES; HUMANS; PEPTIDYL-DIPEPTIDASE A; PULMONARY ARTERY; RENIN;

EID: 84930911674     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313491997     Document Type: Article

References (21)

1. Slater E, Merrill D, Guess H, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. J Amer Med Assoc. 1988 ; 260: 967-970
2. Yang H, Erdos E, Levin Y.. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta. 1970 ; 214: 374-376
3. Leeb-Lundberg L, Marceau F, Muller-Esterl, et al. International union of Pharmacology XLV.Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005 ; 57: 27-77
4. Yang H, Erdos E. Second kininase in human blood plasma. Nature. 1967 ; 215: 1402-1403
5. Sheikh I, Kaplan A. Studies of the digestion of bradykinin, lys-bradykinin, and des-arg9 bradykinin by angiotensin converting enzyme. Biochem Pharmacol. 1986 ; 35: 1951-1956
6. Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 2002 ; 359: 2088-2089
7. Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009 ; 54: 516-523
8. Kostis J, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004 ; 17: 103-111
9. Shiekh I, Kaplan AP. The mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. The role of carboxypeptidase, angiotensin converting enzyme, and determination of final degradation products. Biochem Pharmacol. 1989 ; 38: 993-1000
10. Coldwell PR, Seegal BC, Hsu KC, et al. Angiotensin converting enzyme: Vascular endothelial localization. Science. 1976 ; 191: 1050-1051
11. Zhang X, Tan F, Zhang Y, et al. Carboxypeptidase M and kinin B 1 receptors interact to facilitate efficient B1 signaling from B-2 agonists. J Biol Chem. 2008 ; 283: 7994-8004
12. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003 ; 308: 698-705
13. Gross DM, Sweet CS, Ulm EH, et al. Effect of N-[(S)-1-arboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin 1 pressor responses in vivo. J Pharmacol Exp Ther. 1981 ; 216: 552-557
14. Patchett AA, Harris E, Tristram EW, et al. A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 ; 288: 280-283
15. Kaplan A, Greaves M. Angioedema. J Am Acad Dermatol. 2005 ; 53: 373-388
16. Brown N, Ray W, Snowdon M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996 ; 60: 8-13
17. Gainer J, Nadeau J, Ryder D, et al. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol. 1996 ; 98: 283-287
18. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics. A pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens. 2011 ; 13: 506-516
19. Campbell DJ, Zhang Y, Kelly DJ, et al. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart. Clin Exp Pharmacol Physiol. 2011 ; 38: 623-631
20. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of Factor XII. Proc Natl Acad Sci USA. 2002 ; 99: 896-900
21. White W, Bresalier R, Kaplan A, et al. Safety and tolerability of aliskiren: A pooled analysis of clinical experience in over 12,000 patients. J Clin Hypertens. 2010 ; 12: 765-775